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A B S T R A C T
The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%–21% at 5 years in throm-
botic APS and 20–28% in obstetrical APS [2, 3].
Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-
thrombotic various effects [4–16].
Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European
Medicine Agency.
Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the
use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This
study has been launched in several countries and at now, 53 centers from 16 countries participate to this in-
ternational trial.
This trial consists in two parts: a retrospective and a prospective study.
The French part of the trial in thrombosis has been granted by the French Minister of Health in December
2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by
one of the members of the leading consortium of HIBISCUS.
1. Introduction
Antiphospholipid syndrome (APS) is characterized by the confirmed
presence of antiphospholipid antibodies (aPL) and clinical
manifestations such as thrombosis, and/or pregnancy morbidity and
mortality [1]. APS may occur in the context of a background disease,
autoimmune, mainly systemic lupus erythematosus (SLE) (secondary
APS); when it remains isolated, it represents primary antiphospholipid
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syndrome (primary APS).
Nowadays, there is no drug which possesses the market authoriza-
tion for the treatment of antiphospholipid syndrome (APS). There are
international guidelines that recommend the use of oral vitamin K an-
ticoagulants and/or of antiplatelet drugs for the prevention of throm-
botic relapses and antiplatelet drugs and/or low molecular weight he-
parins for preventing obstetrical relapses.
Nevertheless, despite standard treatments according to international
guidelines, the relapse rate remains high in antiphospholipid syndrome
(APS), i.e. around 20%–21% at 5 years for thrombotic APS and 20–28%
in obstetrical APS [2,3]. Survival rate in this population, most of them
of young people, is low, i.e. at 90.1% at 10 years and 65% at 15 years
[2,3].
New data on the pathogenesis of APS strengthen the need for ad-
ditional or alternative therapies in this disease [4–13].
One of them appeared as one of the best candidates:
Hydroxychloroquine (HCQ).
Several pharmacological mechanisms explain the therapeutic po-
tential of Hydroxychloroquine in rheumatic and related diseases [14].
HCQ have various immunomodulatory, metabolic, cardiovascular,
antithrombotic, and antineoplastic effects [15].
Task force report on antiphospholipid syndrome treatment trends
underlined the need of concentrated efforts to perform large multi-
centric studies based on hydroxychloroquine use in primary and sec-
ondary prevention of relapses in APS [7].
Lastly, during the 15th International Congress on Antiphospholipid
Antibodies (Istanbul 2016) and International Society of Thrombosis and
Hemostasis (ISTH) congress (Berlin 2017) several relevant data focused
on the interest of HCQ in APS [16].
1.1. Why HIBISCUS?
Only a major randomized study such as the HIBISCUS trial could
allow formal conclusions on the potential major benefits of HCQ in
increasing live birth rate in APS and decreasing thrombotic events re-
currence. Therefore, only concentrated international efforts in this rare
disease could allow to conclude on the benefit/risk balance of such a
therapy and to obtain significant benefit data allowing to further apply
for market authorization of HCQ in APS. HIBISCUS is a randomized
versus placebo international trial, with an important number of parti-
cipating centers which will allow a high potential of recruitment and
the statistical power of analysis by subgroups.
Considering the high risk of relapse in APS despite treatment, the
preclinical and clinical preliminary data concerning the benefits of
hydroxychloroquine (HCQ) treatment in APS, our group has applied
and recently obtained the orphan designation of HCQ in antipho-
spholipid syndrome by the European Medicine Agency.
HCQ is therefore designated by the European Commission decision
from 12th January 2017 in the communitarian register of orphan drugs
with the number EU/3/16/1820 and the academic sponsor is the
University Hospital Angers (France).
Moreover, the leaders of the project made the proposal of an in-
ternational project HIBISCUS about the use of Hydroxychloroquine in
secondary prevention of obstetrical and thrombotic new events in pri-
mary APS.
Scientific protocol assistance for the international project HIBISCUS
about the use of Hydroxychloroquine in secondary prevention of ob-
stetrical and thrombotic new events in primary APS has been obtained
from the European Medicine Agency on May 2017 (EurEMA/CHMP/
SAWP/284691/2017 Procedure No. EMEA/H/SA/3509/1/2017/PA/
II).
The project proposal has been launched during the Autoimmunity
Congress (Leipzig April 2016), Europhospholipid Forum (Nancy April
2017), and, lastly, at the scientific session of Lupus anticoagulant SSC
subcommittee ISTH (Berlin, July 2017) and Autoimmunity Congress
(Lisbon, May 2018) [16].
Our consortium has decided to perform this study simultaneously in
several countries.
Fifty three international centers from 16 countries (France, Italy,
Spain, Israel, Portugal, Belgium, The Netherlands, Serbia, Russia,
Romania, Hungary, Turkey, Canada, Tunisia, Argentina, China) joined
the trial HIBISCUS; and the coordinating committee and the scientific
advice committee's members are in the large majority members of the
Europhospholipid group.
The participation of a high number of centers to this trial
strengthens its feasibility and guarantees its success.
The French part of the trial about thrombosis has been granted by
the French Minister of Health in December 2015 (the academic trial
independent of the pharmaceutical industry PHRC N PAPIRUS) co-
ordinated by one of the members of the leading consortium of HIBIS-
CUS.
This trial has two parts: a retrospective study including data which
focus on the effects of HCQ in primary thrombotic and obstetrical APS,
and a prospective study (randomized in some countries and open label
trial in some others).
We will further present the design of this trial based on the previous
preclinical and clinical data.
2. Preclinical and clinical data in thrombotic APS
2.1. Preclinical
Experts underline that there is a need for additional and/or alter-
native therapies in APS and that HCQ could be one of the most inter-
esting therapeutic options [4–9].
New mechanisms were recently described in APS [4,17]. The anti-
bodies against the domain I of β2 glycoprotein I (β2GPI) are recognized
as the main pathogenic subset in APS.
HCQ interacts with toll-like receptors [18]; inhibits calcium-de-
pendent cell signaling [19] and reverses platelet activation induced by
aPL [20].
HCQ significantly reduces the production of cytokines (IL-6, IL-8, IL-
17 and IL-22 and TNF-α, Il-1, soluble CD8 and soluble IL2 receptors)
and induces the normalization of complement activity [21,22].
In addition to the known mechanisms on platelets activity
[20,23,24], intravascular red blood cell aggregation inhibition [25],
reduction of APL IgG-B2GP1 complex binding to phospholipid layers
[26]; protection of the anticoagulant shield formed by annexin V from
damage by APL [27], cholesterol reduction, reduction of APL produc-
tion, recent data have focused on new mechanisms of action of HCQ in
preventing thrombosis [28–30].
It has been reported that upon binding, APL trigger intracellular
mediators such as nuclear factor kappa B and mammalian target of
rapamycin [4].
Hydroxychloroquine exerts not only immunomodulatory effects
[15], but it also inhibits proinflammatory signaling pathways by tar-
geting endosomal NADPH oxidase [28], and significantly reduces so-
luble TF levels in patients with aPL [29].
Long-term use of hydroxychloroquine reduces antiphospholipid
antibodies levels in patients with primary antiphospholipid syndrome
[30] and is associated with lower odds of persistently positive aPL in
SLE patients [31].
Finally, hydroxychloroquine treatment might be useful to control
type I IFN-related immune activation in PAPS [32].
2.2. Clinical
The data available from literature pertain mainly to secondary APS,
as few data have been published for primary APS [30,33].
Our team has shown the role of hydroxychloroquine (added to
standard oral anticoagulants) in reducing the incidence of new venous
thrombosis in primary APS patients [33].
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We have reported a striking significant difference in a preliminary
study in primary APS patients in terms of thrombotic relapses in a
comparative population treated with HCQ and AVK versus AVK alone.
Therefore, after three years of treatment, we have observed new
thrombotic events in 30% of patients from the group VKA alone; and no
new thromboses in the group treated by HCQ and VKA [33].
To our knowledge, this was the first prospective study performed in
primary APS.
A recent retrospective, propensity score-matched cohort study,
which analysed the impact of HCQ on aPL titers and the incidence of
thrombotic events in 57 APS APS patients treated with HCQ compared
to 57 not exposed patients has shown the beneficial effects exerted by
HCQ both in lowering aPl titers and on a significant reduction in the
incidence of arterial events (0 vs 1.14%) [30].
A large panel of studies focuses on the benefits of HCQ as an anti-
thrombotic in lupus and in APS secondary to SLE [15,34–46].
It has been reported that the use of HCQ was associated with a re-
duction in thrombotic risk [42–43,45–47]. HCQ administration was
inversely correlated with the onset of thrombosis, kidney failure, hy-
pertension and infection, and directly correlated with improved sur-
vival rates in lupus patients [48].
A case-control study on a population of lupus patients revealed by
multivariate analyses, a 68% reduction of thrombotic risk (26–86%)
under HCQ treatment, notably after correction for disease severity,
monitoring time and disease duration (OR 0.32, 95% CI 0.14–0.74)
[39].
These data were however controversial as the study of Tektonidou
et al. failed to show any thrombotic risk reduction in the presence of
HCQ [49]. However, this trial had several limitations, as 55% of APL+
patients possessed additional thrombosis factors, and even though it
was a longitudinal study, the collected data were retrospective.
The rate of survival estimated over 15 years was 68% in patients
naïve to antimalarials against 95% in patients treated by antimalarials
[46].
These data account for a decrease of 77% of mortality with anti-
malarials.
A meta-analysis of 95 articles pertaining to randomized prospective
studies and observational studies concluded that HCQ has multiple
beneficial effects, including anti-thrombotic properties, with a mod-
erate level of evidence [41].
The study of the international consortium “APS action” which in-
tended to show a beneficial effect of HCQ in healthy people with po-
sitive aPL but no clinical events (aPL carriers), failed, as a relatively
short follow-up was performed, and also as authors could not accurately
assess the effectiveness of HCQ for primary thrombosis prevention in
persistently PL-positive patients with no other systemic autoimmune
diseases [50].
All these data are only preliminary and therefore there is a need of a
large prospective study that we propose: a national French study fi-
nanced in 2015 (PHRC N PAPIRUS) and further the international study
HIBISCUS.
As nowadays most of SLE patients receive HCQ as basal treatment,
only a study in primary thrombotic APS could provide the evidence of
this treatment for the secondary prevention of thrombosis.
Thus, based on all these data dealing with the significant risk of
thrombotic relapse, occurring under appropriate treatment, we propose
the use of HCQ additionally to standard anticoagulant treatment for the
prevention of thrombosis relapse in antiphospholipid syndrome.
3. Preclinical and clinical data in obstetrical APS
Experts accord in proposing HCQ as an additional therapy in re-
fractory obstetrical APS [51–55].
3.1. Preclinical
The pathogenesis of obstetrical APS implies several mechanisms,
such as prothrombotic state including inhibition of β2-GPI activity,
platelet activation, tissue factor upregulation and annexin A5 resistance
reducing anticoagulant activity of annexin A5 [10,56]. Trophoblast
injury implies trophoblast cell apoptosis, impairment of invasiveness,
and increased number of inflammatory cells and cytokines in placental
bench.
Experimental models showed that HCQ may restore some defective
biological functions induced by anti-phospholipid antibodies (aPL) on
trophoblasts and some studies reported a protective effect on in vivo
aPL-mediated placental and foetal neurodevelopmental abnormalities
in an animal model of aPL-mediated foetal loss [57,58].
HCQ display a pleiotropic activity spanning from immunomodula-
tion effect to anti-inflammatory and anti-thrombotic activities, all of
them being potentially useful in APS. The well-known safety of HCQ in
pregnancy encouraged for its use in pregnant women with autoimmune
rheumatic disorders including APS and observational reports suggested
a protective effect on obstetrical recurrences.
Since thrombosis is only one of the pathogenic mechanisms in ob-
stetrical APS, the efficacy of HCQ is also related to other pharmacolo-
gical effects.
Several in vitro studies demonstrated that hydroxychloroquine can
reduce the aPL antibody binding to syncytiotrophoblasts and restore
annexin A5 expression and functional anticoagulant activity [59]. Hy-
droxychloroquine could also antagonize aPL-mediated inhibition of
trophoblast migration, invasion and differentiation [58,60,61]. More-
over, it has been reported that Hydroxychloroquine reversed the aPL-
inhibition of trophoblast IL-6 secretion and partially limited aPL-in-
hibition of cell migration [58].
As anti-β2GP1 antibodies decrease trophoblastic differentiation via
TLR4, it has been reported that this effect is restored by HCQ, sug-
gesting its therapeutic interest in APS pregnancies [60]. The effect of
Hydroxychloroquine on antiphospholipid antibody-induced changes in
first trimester trophoblast function are beneficial [58,62]. Furthermore,
it has been reported that HCQ is able to dramatically reduce the anti-
phospholipid antibodies levels in obstetrical APS [9].
3.2. Clinical studies
Observational studies and reports focussed on additional ther-
apeutic strategies in refractory cases of obstetrical APS. Nowadays, the
best therapy regimen for refractory obstetrical antiphospholipid syn-
drome remains to be determined: additional treatments with steroids,
plasma exchanges and immunoglobulins, HCQ.
Among these alternatives, hydroxychloroquine (HCQ) is one of the
most interesting therapeutic options.
Beneficial effects of HCQ therapy during pregnancy in SLE have
been reported since long date [63]. HCQ reduces neonatal morbidity in
women with SLE by significantly decreasing the rate of prematurity and
intrauterine growth restriction [64] and is linked to a significantly
higher live birth rate [51].
There are no randomized clinical trials on the use of HCQ to prevent
recurrent miscarriages in APS patients.
There are several case reports [53,65] or case series, and among
them our preliminary study, that reported the effects of HCQ in pre-
venting obstetrical relapses. Most of the studies are retrospective and
concern a heterogenous APS population (primary and secondary APS,
asymptomatic APS and refractory obstetrical APS, with different addi-
tional and/or rescue treatments).
Therefore, for refractory APS few case reports and the obstetrical
series of the Europhospholipid group strongly suggest the usefulness of
HCQ in preventing obstetrical relapses [10,53,54,61,66,67].
Observational/retrospective studies on the protective role of HCQ
on pregnancy complications in APS were recently published.
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Ruffatti et al. reported in 194 pregnant PAPS patients attending 20
tertiary centers retrospectively enrolled that Hydroxychloroquine was
found to be linked to a significantly higher live birth rate with respect
to the other oral treatments [51]. Moreover, the high (400mg) versus
low (200mg) doses of hydroxychloroquine (p= .036) and its admin-
istration before versus during pregnancy (p= .021) were associated
with a significantly higher live birth rate [51].
Leroux M et al. evaluated the effect of HCQ on fetal preterm delivery
and intrauterine growth restriction (IUGR) in a cohort of pregnant
women with SLE including a small series positive for aPL [64]. HCQ
reduced neonatal morbidity in all of the SLE women by significant
decrease of the rate of prematurity and intrauterine growth restriction
[64].
A total of 118 pregnancies were included over 11 years, 41 in the
HCQ+ group and 77 in the HCQ- group. The rate of adverse fetal
outcome was significantly lower in the HCQ+ group (p= .001) [64].
Two other studies included also primary APS and reported a de-
crease in pregnancy losses in the treated group; moreover, the addition
of HCQ resulted in a significant increase in live births in the refractory
group [10,67].
Hydroxychloroquine treatment was associated with a higher rate of
live births (67% group A vs 57% group B; p= .05) and a lower pre-
valence of antiphospholipid antibodies-related pregnancy morbidity
(47% group A vs 63% B; P= .004). The association of hydroxy-
chloroquine with a lower rate of any complication in pregnancy was
confirmed after multivariate analysis (odds ratio, 2.2; 95% confidence
interval, 1.2–136; P= .04). Fetal losses at> 10weeks of gestation (2%
vs 11%; P= .05) and placenta-mediated complications (2% vs 11%;
P= .05) were less frequent in group A than group B [67].
In the European multicentre study leaded by the Europhospholipid
group, the outcome of pregnancies treated by hydroxychloroquine in
patients with APS or asymptomatic antiphospholipid (aPL) antibodies
carriers were analysed [10,66]. Thirty patients with APS with 35
pregnancies treated by hydroxychloroquine were analysed. Comparing
the outcome of pregnancies treated by the addition of hydroxy-
chloroquine to previous pregnancies under the conventional treatment,
pregnancy losses decreased from 81% to 19% (p < .05), without dif-
ferences in the associated treatments. The univariate analysis showed
that the previous intrauterine deaths and higher hydroxychloroquine
amount (400mg per day) were the factors associated with pregnancy
outcome. Considering 14 patients with previous refractory obstetrical
APS (n=5 with obstetrical and thrombotic primary APS and n=9
with purely obstetrical APS), all with previous pregnancy losses under
treatment (aspirin with LMWH in 11 cases and LMWH in 3 cases), the
addition of hydroxychloroquine resulted in live born babies in 11/14
(78%) cases (p < .05) [10,54].
However, the effect of HCQ was not adjusted for the use of other
medications such as aspirin, heparins or steroids [10]. Selected experts
agreed that adding HCQ could be considered in selected cases or after
failure of standard treatment with aspirin and a heparin [10]. Specifi-
cally, most experts considered adding HCQ in specific situations:
women with previous thrombosis, and/or with placenta-mediated
complications, when a high risk aPL profile or concomitant cardiovas-
cular risk factors are present or in case of allergy/intolerance to aspirin
[10,66].
Nevertheless, prospective well-designed studies are needed to con-
clude on the efficacy of HCQ in preventing miscarriages in APS and all
experts are agreeing with this item.
Our group has recently performed a study in obstetrical APS [16].
There is only a preliminary prospective study about Hydroxy-
chloroquine effects on preventing miscarriages in obstetrical primary
APS refractory to standard therapy (curative doses low molecular
weight heparins plus aspirin). The APS population was homogenous
and consisted in refractory obstetrical APS with maximal standard
treatment and fulfilling the Sidney criteria. 13/14 pregnancies were
followed by a live normal birth in this preliminary report.
The available data in the literature about HCQ efficacy in obstetrical
APS are summarized in Table 1.
These data suggest that the HCQ adjunction to treatment was suc-
cessful in 11/14 cases (78%) in the retrospective series of Mekinian
[10] et al. and 13/14 cases (93%) in our preliminary prospective trial
[16].
Based on these data, on sporadically successful case reports and
series of live birth when adding HCQ to standard therapy, we suggest a
major beneficial effect of HCQ in preventing miscarriages in refractory
primary APS patients.
A recent international trial HYPATIA: Hydroxychloroquine to
Improve Pregnancy Outcome in Women with Antiphospholipid
Antibodies (HYPATIA) Protocol: A Multinational Randomized
Controlled Trial of Hydroxychloroquine versus Placebo in Addition to
Standard Treatment in Pregnant Women with Antiphospholipid
Syndrome or Antibodies was also launched in September 2017 [68].
We further propose the HIBISCUS trial: we hypothesize that HCQ
added to standard therapy could significantly improve birth rate in
primary obstetrical APS. The trial is based on the hypothesis of 80%
obstetrical events for the entire studied APS population.
We expect a 15% increase of birth rate with HCQ treatment ad-
ministered in addition to the standard treatment for APS, i.e. a 95% live
rate birth in the HCQ group. The study will be performed as a rando-
mized clinical trial or as an open trial in the different 16 participating
countries of the consortium.
4. Design of the clinical trial HIBISCUS
HIBISCUS is an international multicentric, comparative, rando-
mized, double-blinded, controlled versus placebo study. This is a phase
III drug trial.
Patients will be distributed into groups according to a 1:1 ratio.
Therefore, this trial shall focus on a population of patients with
primary antiphospholipid syndrome. Although initially we have de-
signed for ethical reasons and to avoid stress during pregnancy an open
label study, after the scientific advice of the European Medicine Agency
Table 1
Data with respect to HCQ efficacy in obstetrical APS.
Reference Country Methodology Number of cases Patients treated with HCQ
66 European
The EUROAPS register led by the Europhospholipid
group
Retrospective 247 3
10 European Retrospective 30 14 including also asymptomatic aPL carriers without previous obstetrical
manifestations
9 Italy Case report 1 1
65 USA Case report 1 1
16 France Prospective 14 14
67 Italy and England retrospective 96 31
64 France retrospective 118 41
51 International retrospective 194
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and discussion with the members of our national and International
scientific consortium, we have finally decided to perform a double
blinded randomized study, to get formal conclusions with significant
statistical power. Furthermore, the patients will be informed that their
participation to the trial is not a loss of chance, as they will be treated
with the optimal standard of care therapy according to international
guidelines.
4.1. Design of HIBISCUS trial in obstetrical APS: HIBISCUS-O
4.1.1. Main goal and main outcome measure
The main aim of this trial is to assess the number of live births in
primary antiphospholipid syndrome in patients treated with
Hydroxychloroquine added to standard treatment i.e. low molecular
weight heparins at preventive dosage and aspirin, in a multicentre,
prospective randomized, double-blind, versus placebo study.
Synopsis of obstetrical APS.
Main aim The main aim of this trial is to assess the
number of live births in primary
antiphospholipid syndrome in patients
treated with Hydroxychloroquine added to
standard treatment i.e. low molecular weight
heparins at preventive dosage and aspirin, in
a multicentre, prospective randomized,
double-blind, versus placebo study
Secondary goals - Analysis of adverse reactions and their
severity in Hydroxychloroquine plus
LMWH and aspirin group
- Analysis of the time of occurrence of
adverse effects
- Analysis of maternal morbidity related to
primary APS, including miscarriage as well
as late pregnancy complications like fetal
deaths and premature delivery related to
eclampsia/pre-eclampsia
- Analysis or fetal morbidity: intrauterine
growth retardation and premature birth
- Using standard basic tests, define
predictive biological parameters of the
occurrence of pregnancy morbidity events
at inclusion and at the end of the trial (such
as lupus anticoagulant positivity prior to
heparin treatment, triple aPL positivity,
thrombocytosis, complement C3, C4,
CH50, C reactive protein, cholesterol,
blood level of hydroxychloroquine at the
end of the trial)
- Measure of compliance to HCQ
Primary outcome
measure
- The number and percentage of live births
in each arm. The percentages of these
events will be compared by appropriate
statistical test (Chi2 test or Fisher exact
method)
Secondary outcome
measures
- The type and number of adverse
reactions and their severity (minor/
major) in Hydroxychloroquine group.
The conventional definitions for severity
will be used (i.e. death, life-threatening,
hospitalization/prolongation of
hospitalization, persistent or significant
disability/incapacity, as defined by
current pharmacovigilance standards.
- The occurrence time of side effects
measured every 3months and at the end of
the study.
- Morbidity related to pregnancy morbidity
events (hospitalization, temporary work
incapacity, miscarriage, fetal deaths and
premature birth), in each arm, as well as
the confidence interval, will be evaluated
after maximum 9months of treatment (end
of the pregnancy).
- Predictive biological standard basic
parameters of the occurrence of pregnancy
morbidity event at the inclusion and at the
end of the trial (such as lupus
anticoagulant positivity prior to heparin
treatment, triple aPL positivity,
thrombocytosis, complement C3, C4,
CH50, protein C reactive, lipid profile
(total cholesterol, and HDL, LDL
cholesterol), blood level of
hydroxychloroquine at the end of the trial).
- Dosage of blood level of
hydroxychloroquine at the end of the trial
will allow the measure of compliance to
HCQ.
End points will be assessed at the end of the
study by statistical analysis
Study methodology/
scheme
This is a phase III drug trial, international
multicentric, comparative, randomized,
superiority, double-blinded, controlled with
2 compared groups (Hydroxychloroquine
versus placebo) study.
Patients will be distributed into groups
according to a 1:1 ratio.
Patients will be enrolled at multiple centres
by internists, rheumatologists, nephrologists,
angiologists, cardiologists, neurologists and
vascular medicine and all other specialists.
Patients monitored in the context of their
disease (primary APS), or with primary APS
newly diagnosed, will be invited to take part
in the trial (incident and prevalent cases).
Women with primary obstetrical APS willing
a pregnancy will be informed about the
study. When they will stop contraception
and/or wish to start a new pregnancy for
women without contraception, or the
pregnancy is confirmed (but prior to
12weeks of gestation) a pre-treatment with
Aspirin 160mg/day, that is the standard
therapy of care will be started. This
treatment will be continued all long
pregnancy.
Now when the pregnancy will be confirmed
by BHCG dosage or echography attesting
foetal cardiac activity, after informing again
the patient and obtaining his/her signature
on the informed consent form, the
investigator will fill in a computerised pre-
inclusion form, available 24/7 over the
Internet via the e-CRF (secure access
previously granted to each pre-declared
investigating centre).
• An ophthalmological visit will be
scheduled prior to inclusion.
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The patients will be randomized to
additionally receive either LMWH at
preventive dosage plus HCQ in arm A or
LMWH at preventive dosage plus placebo in
arm B. The experimental treatment will be
HCQ. The standard treatment will be LMWH
and Aspirin as the international guidelines
indicate the use of LMWH at preventive
dosage plus Aspirin in case of refractory
obstetrical APS despite treatment with
Aspirin.
Randomisation will be centralised and
implemented by a computerised random
allocation system coupled with the electronic
case report form, such that patients included
in the study can be easily and automatically
randomized. The randomisation number will
be identical to the treatment number
displayed on the treatment kit (box) labels.
The study treatment will be prescribed
(sponsor prescription) and the inclusion
confirmation will be faxed to the coordinating
centre
The investigator shall perform several data
checks and collections during the study.
During each patient report, the inclusion and
non-inclusion criteria will be checked.
Therefore, at the inclusion visit it will be
performed:
- Verification of patient eligibility criteria
- Confirmation of pregnancy by BHCG
dosage or echography attesting foetal
cardiac activity
- Verification of the absence of ECG
conduction disorders
- Obtaining the patient’s informed consent
- Obtaining the patient’s clinical-biological
information (standardised data sheet)
- Verification of normality of initial
ophthalmic examination
- Fax to the Angers University Hospital
central pharmacy for randomisation
(numbered kits will be provided in advance
in participating investigating departments)
- Initiation of treatment: HCQ or placebo, at
a dose of 200mg×2/day taken once daily
(adapted to 200mg/day in women with a
weight < 45 kilos).
Dispensation of the treatment every 3months
by the Pharmacy Department in each centre.
Empty or not entirely empty flask will be
contabilized and pills will be counted at each
new dispensation.
Follow-up:
• Blood tests at M1, M2, M3 to check out the
tolerance of HCQ (cell blood count CBC,
liver enzymes: ASAT/ALAT). They will be
performed during a monthly routine test
for platelets dosage and antiXa activity (to
follow LMWH tolerance and dosage range).• Electrocardiogram (ECG) will be
performed at inclusion in the study and at
M1, M2, M3 as cardiovascular potential
side effects of HCQ even though rare could
appear early after the initiation of the
treatment.• Close monitoring of the pregnancy will be
performed monthly by the obstetrician
(these visits belong to the standard follow-
up of patients with primary APS).• A close monitoring of the fetus by
echography during pregnancy to detect
any adverse situation and characterize the
safety of the fetus will be performed
monthly by the obstetrician (these
monitoring belongs to the standard follow-
up of patients with primary APS).• The observance and tolerance of the
treatment will be followed up every
month by the internist/rheumatologist/
nephrologist or any other specialist co-
investigator of the trial that insures the
regular follow-up of the patient for the
primary APS via an in site medical visit,
and data will be completed on a simplified
eCRF standardised file (a part of these
visits belong to the standard follow-up of
patients with primary APS).
*Although the specialists that insure the
follow-up of the patients for the APS see them
regularly in routine every 2–3months during
pregnancy, we have decided to schedule these
visits monthly for monitoring the safety of the
pregnant women and foetus.
• An ophthalmological visit will be
scheduled during the sixth month of
pregnancy and in case of any doubt on
ophthalmological impairment the HCQ
will be stopped.• At the end of the pregnancy HCQ blood
dosage will be performed during a routine
monthly biological test.• Long term follow up to discard any late
onset effects (i.e. audition or visual defects)
will be planned via a medical visit of the
child at one year and at two years
performed by pediatricians in each center,
co-investigators in the trial.
All non-serious adverse event and/or
abnormal results defined as critical to the
evaluation of the safety of the test subjects,
must be reported to the sponsor by the
investigator, in accordance with the SAR
reporting rules.
24months for inclusion and maximum 9 mo
(until delivery) of follow-up will be scheduled.
Statistical analysis will be performed at the
end of the trial, one intermediate analysis is
planned after the inclusion of the first 40
patients and at each 40 patients included.
In summary biological and complementary
tests during the study:
- Profile on inclusion visit D0 consisting in full
blood test and platelets, creatinine, liver
tests (ASAT, ALAT), C reactive protein
(CRP), cholesterol (total, HDL, LDL)
hemostasis test, i.e. prothrombin time,
TCA, fibrinogen; antiphospholipid
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antibodies (lupus circulating
anticoagulant, anticardiolipin antibody,
anti-B2GP1 antibody), antinuclear
antibody (ANA) assay with determination
of anti-DNA and anti-ENA if anti-ANA
antibodies positive. These blood tests are
part of the normal follow-up for a patient
suffering from APS. This follow-up shall be
charged to the patient's health insurance.
- at M1, M2, M3 full blood count cells test
(minor risk of agranulocytosis). These are
also blood tests included in routine.
- at M1, M2, M3 ALAT and ALAT (minor risk
of hepatitis) and ECG. The additional blood
tests will be performed during a monthly
routine blood test for platelets dosage and
antiXa activity (to follow LMWH tolerance
and dosage range).
Although these blood tests could be scheduled
only in the first month, we have chosen to
perform them from M1 monthly until M3 to
avoid any unknown side effects, considering
the fragile population of pregnant women.
Moreover, these tests will be performed during
a routine monthly blood test, and no
additional blood volume is needed.
- Monthly creatinine, urinary bandelette, C
reactive protein, hemostasis test, i.e. TP,
TCA, fibrinogen. This will be biological
tests included in routine.
- At M3, M6 and M9 visit: the blood tests
will be identical to those performed on
inclusion visits (with the exclusion of lupus
anticoagulant that would be no reliable
due to the LMWH ongoing treatment).
All these blood tests are part of the normal
follow-up for a patient suffering of APS. This
follow-up shall be charged to the patient's
health insurance.
- Hydroxychloroquine blood dosage will be
exclusively performed at the end of
pregnancy during a routine monthly blood
test (to insure to the compliance to
treatment, but also to not affect the double-
blind character of the trial).
This will be an additional biological test, not
included in routine.
The additional examinations will be in
summary
1. Ophthalmic examination prior to inclusion
and at 6months
2. ECG at M1, M2, M3
3. ASAT/ALAT at M1, M2, M3 during a
monthly blood test (without an additional
blood volume requested)
4. Four additional clinical visits by specialists
that insure the follow-up of the mother
monthly for APS (instead of every
2–3months as performed in routine follow-
up).
5. Hydroxychloroquine blood dosage will be
exclusively performed at the end of
pregnancy
6. Two medical visits of the child (at one year
and at two years) performed by
pediatricians in each center, co-
investigators in the trial.
Unblinding and statistical analysis shall be
performed at the end of the trial, i.e. at
33months. Intermediate statistical analyses
every 40 patients included are planned.
An independent committee survey will check
that there is no abnormal rate of events in one
of the arms of the study every 40 included
patients or at least once yearly, to check the
clinical and biological tolerance of the
experimental drug.
An independent committee of adjudication of
obstetrical events will deliberate on the
confirmation of obstetrical relapses.
As the trial involves interventional biomedical
research, it shall be declared to the competent
authorities in each country and shall be
subject to IRB approval
Subject inclusion
criteria
• Age >18 years• With primary* obstetrical antiphospholipid
syndrome**according to Sidney criteria,
with one of the following 2 criteria:
1. 3 or > 3 consecutive spontaneous
abortions < 10weeks of gestation with
maternal anatomic or hormonal
abnormalities and paternal and maternal
chromosomal abnormalities excluded
2. or one or more unexplained deaths of a
morphologically normal fetus at or beyond
the 10th weeks of gestation, with normal
morphology detected by ultrasound or by
direct examination of the fetus• Willing to be pregnant or being pregnant
< 12weeks (pregnancy confirmed by
BHCG dosage or cardiac fetal activity on
echography)• Patients are volunteers, informed and
signed the consent form for participation in
the study after receiving the information
letter.• *Primary APS refers to APS with no
identified cause.
**According to the Sydney international
criteria, obstetrical antiphospholipid
syndrome is evidenced by the presence of an
obstetrical clinical manifestation, combined
with the presence of a biological criterion:
presence of circulating anticoagulant and/or
of anticardiolipin antibodies > 40 uGPL
(> 99 percentiles) and/or anti-B2GP1
antibodies > 40 uGPL (> 99 percentiles).
The presence of antiphospholipid antibodies
(aPL) should be confirmed to 3months for an
APS be recognized.
Obstetrical manifestations are defined
according to international criteria as
• 3 or > 3 consecutive spontaneous
abortions < 10weeks of gestation with
maternal anatomic or hormonal
abnormalities and paternal and maternal
chromosomal abnormalities excluded
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• or one or more unexplained deaths of a
morphologically normal fetus at or beyond
the 10th weeks of gestation, with normal
morphology detected by ultrasound or by
direct examination of the fetus• or one or more premature births of a
morphologically normal neonate before
the 34th week of gestation related to pre-
eclampsia/eclampsia or recognized
features of placental insufficiency
The trial has taken the choice of using (> 99
percentiles) to insure the homogeneity and
reliability of tests in the different co-
investigator centers
Subject non-inclusion
criteria
• Secondary APS• The following ophthalmological disease:
○ retinal disease contraindicating
Hydroxychloroquine prescription
○ cataract
○ monophthalmia• Demonstrated history of HCQ intolerance/
allergy or HCQ contraindication• Known glucose-6-phosphate
dehydrogenase deficiency• Chronic liver disease• Renal failure (creatinine clearance
<30ml/min)• Chronic alcoholism• Patients with already increased QT values• Concurrent treatment with other products
potentially increasing QT or with
arrhythmogenic properties• Epilepsy• Haemolytic anaemia• Porphyria• Progressive ongoing cancer or
hematological malignancy• Psychiatric disease not allowing the
treatment• Lack of health insurance• *Participation to concomitant study with
interventions leading to a bias to our study
(other drugs, with synergistic or
antagonizing or confounding effects).• History of heparin-induced
thrombocytopenia (HIT) (with or without
thrombosis)• Uncontrolled, active bleeding• Conditions in which coagulation tests
cannot be performed at appropriate
intervals• Known hypersensitivity to heparin or pork
products• Any risk factor for hemorrhage (e.g.,
subacute bacterial endocarditis, blood
dyscrasias, menorrhagia, dissecting
aneurysm, major surgery, spinal
anesthesia, hemophilia, GI ulcerative
lesions, liver disease, impaired hemostasis)
*In case of doubt with respect to this criterion
the coordinator of the study will be contacted
and will deliberate about the possibility to
participate to a concomitant trial
Treatments/
strategies/
Procedures
The treatment for prevention of pregnancy
morbidity relapses will consist in low
molecular weight heparins at preventive
dosage and aspirin plus HCQ in arm A and
plus placebo in arm B. To insure the
homogeneity of the study and to follow the
standard practice procedures, we have
decided that one singe dosage of Aspirin to
be used 160mg/day, and one type of LMWH:
Lovenox (Sodic Enoxaparin) 4000 UI or
0.4ml/sc/day.
The Aspirin dose is the dose the most
prescribed by experts. Lovenox is the
standard LMWH in France most frequently
used in preventive intention. One single
subcutaneous injection 4000 UI (0.4ml) will
be administered daily until the last trimester
of pregnancy (until at least 35th week of
gestation and the latest to be stopped 12 h
prior to delivery).
Patients shall be randomized in a double-
blind manner to receive either HCQ or the
placebo. The ratio of patients randomized
into the two groups shall be of 1:1.
Randomisation will be implemented by a
computerised random allocation system
coupled with the electronic case report form,
such that patients included in the study can
be easily and automatically randomized.
The randomisation number will be identical
to the treatment number displayed on the
treatment kit (box) labels.
The choice of a 400mg dose seemed
appropriate as this is below the toxic dose
(< 6.5mg/kg/d) and is routinely used in
cases of SLE and RA. This dose corresponds
to an average of 6mg/kg/day, the
recommended dose for patients with no
associated risk factors. Patients with such
risk factors will be excluded from the trial.
The doses used in the literature to
demonstrate the effect of HCQ obstetrical
relapse are equal to this dose. Critical review
of the current recommendations for the
treatment of systemic inflammatory
rheumatic diseases during pregnancy and
lactation [69,71] and the EULAR points to
consider for use of antirheumatic drugs
before pregnancy, and during pregnancy and
lactation [70,71] have been recently
published. The report of the European
League Against Rheumatism (EULAR) task
force on use of anti-rheumatic drugs before
pregnancy, and during pregnancy and
lactation suggested that HCQ should be
continued in pregnancy for maintenance of
remission or treatment of a disease flare
(Grade B of recommendation, strength of
evidence according to GRADE Oxford 2°)
[70,71].
Considering the drug’s expected benefits
associated with its use, we deemed it ethical
to propose these doses over a 9-month
period.
The patients’ other primary treatments will
not be altered and will remain freely chosen
by the investigator. The benefit-risk balance
of this drug would appear acceptable at the
individual and collective levels.
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A weight-adjusted dose regiment: 200mg
daily will be administered for patients
weighing <45 kg.
The results of this trial could, at minimal cost
and with highly favorable benefits to risks
ratio, allow a significant improvement in the
management of patients with primary APS
and reduce the incidence of pregnancy
morbidity and improve natality in this
population
Number of Patients Number of subjects required to answer the
research question: 170 in each group, i.e.
340
Justification of the
sample size
The increase in birth rate using HCQ added
to standard therapy in refractory APS was
suggested to us by the data of the literature
showing a decreased relapse of obstetrical
manifestations varying from 78 to 95%, and
respectively an increased in birth rate of at
least 15% [10,16,66].
The sample size calculation is based on the
following justifications: as the number of
live births in APS patients failing to maximal
standard therapy with LMWH and aspirin is
80%; the clinical relevance of the proposed
primary endpoint is numerically defined as
an expected increase with 10%; i.e. 90% of
live births in the experimental group.
Although we could have chosen the low
range of rate of live births i.e. 70–75% for
the statistical analysis, and even though our
approach would increase the size of the
population, we have preferred to use the
high range i.e. 80% of range of rate of live
births in the control group to get formal
undeniable conclusion on the balance
benefit/risks of HCQ use in this fragile
population with a sufficient statistical
power.
If the live birth rate is of 80% in the control
group, assuming a 10% increase in the
studied group in a primary APS population
receiving HCQ then 308 patients (154 per
group) must be included (Biostat TGV on
unilateral formulation with a first order risk
alpha of 0.05 and a statistical power of
80%). Considering 20% of drop-outs a
number of 340 patients will be necessary
(170 per group). We make this assumption
based on all preclinical and clinical existing
data and on all preliminary indirect data.
Although we are aware of the limits of a 20%
dropout, as the pregnant women will be
informed that there is no loss of chance in
the placebo arm as we follow international
guidelines of therapy in refractory to Aspirin
obstetrical APS, we are confident that the
adhesion of pregnant APS women will be
important.
Patients will remain in the trial, even after
discontinuation for adverse event or
toxicology reasons to collect data facilitating
interpretation of missing data (loss of
patients, drop outs for safety) at the end of
the trial (intention to treat protocol).
The non-responder approach would be
deemed conservative and preferred as the
main method for managing missing values.
Other methods dealing with missing data
will be also included as sensitivity analyses.
As an example, multiple imputation, hybrid
methods where treatment-related drop-outs
(i.e. due to lack of efficacy or safety events)
are treated as no-responders and all non-
treatment related dropouts are managed
through multiple imputation, or observed
cases only analysis, may also be included as
sensitivity analyses
Statistics Descriptive statistics: Collected variables
shall be described globally and per group.
Qualitative variables are expressed in
population size and percentage. Quantitative
variables are expressed in terms of
mean ± standard deviation with 95%
confidence interval, along with the 5th and
95th percentiles. These are, however,
expressed in terms of median, minimum,
maximum and 5th and 95th percentiles
when normality is rejected. The
Kolmogorov- Smirnov test will be used to
check parameter normality and the Levene
test will be used to determine equality of
variances.
The Student t test will be used to compare
the distribution of quantitative variables
between the two patient groups (Plaquenil/
placebo). If the test application conditions
are not met, the Mann-Whitney non-
parametric test will be used. The Chi-square
or Fisher exact-test will be used to compare
the distributions of qualitative variables
between the two groups.
Goals analysis
The analysis of the main outcome measure
shall consist in comparing the proportions of
live births in the two groups. This
comparison shall be performed by means of
a Chi-square test, or a Fisher exact-test if the
Chi-square application conditions are not
met. If a difference between the two groups
is demonstrated for at least one of the
potential confounding variables, the main
outcome measure shall be analysed by
means of multivariate logistic regression to
consider the adjustment factors.
The secondary outcome measures will be
analysed using the same methods as the main
outcome measure. A survival analysis related
to the risk of live births failure during
follow-up associated with the exposure
factor shall be performed and estimate by
calculating the hazard ratio (uni- and
multivariate Cox model).
We will perform analysis based on type of
antiphospholipid antibodies types and
values (low, moderate and high) and type of
previous obstetrical event (event prior to
inclusion) and we will analyse the
tendencies.
Intermediate analyses will be performed at
each 40-patient’s inclusion.
In this case complete descriptive statistics
C. Belizna et al. Autoimmunity Reviews 17 (2018) 1153–1168
1162
will be conducted. Comparative analysis will
be driven if statistical power is sufficient. In
case an increased number of adverse events
recorded at each intermediary analysis in
one of the arms of the study the trial will be
stopped according to the supervisor
committee advices
Research duration Considering the low prevalence of primary
obstetrical APS in the general population,
the total patient inclusion period shall be of
2 years, taking trial duration to maximum
33months.
Thus:
Inclusions: 24months
Follow-up: maximum 9months (until
delivery)
A total duration of maximum 33months
4.2. Design of HIBISCUS trial in thrombotic APS: HIBISCUS-T
This is a phase III drug trial, international multicentric, compara-
tive, randomized, superiority, double-blind, controlled with 2 com-
pared groups (Hydroxychloroquine versus placebo) study.
The study proposed is a phase III randomized double-blinded trial
with two arms: patients in Arm A will receive vitamin K anticoagulants
(VKA) and Hydroxychloroquine (HCQ). Patients in Arm B will receive
VKA plus placebo. The inclusion period will be 24months and Arm A
and Arm B will receive treatment 24months (total study duration
48months). The patients will have supplementary 3months survey
after the end of the study.
4.2.1. The main aim
The main aim of this trial is to assess at 24months the efficacy of
treatment with Hydroxychloroquine in preventing new thrombotic
events (venous and arterial) in primary antiphospholipid syndrome in
patients treated with VKA with a target INR between 2 and 3, in a
multicenter, prospective randomized, double-blind, versus placebo
study. The main end points will be the number and the percentage of
new thrombotic events in each arm at the end of the study
HIBISCUS trial in thrombotic APS: HIBISCUS-T.
Main aim The main aim of this trial is to assess at
24months the efficacity of treatment with
HCQ in preventing new thrombotic events in
primary antiphospholipid syndrome in
patients treated with VKA, in a multicentre,
international, prospective randomized,
double-blind, versus placebo study
Secondary goals - Analysis of adverse reactions and their
severity in the HCQ plus VKA group.
- Analysis of the time of occurrence of
adverse reactions.
- Using standard basic tests, define
predictive biological parameters of the
occurrence of thrombotic events at the
inclusion, M12 and M24.
- Measure of compliance to HCQ
End points will be assessed at the end of the
study by statistical analysis
Primary outcome
measure
- The number and percentage of
thrombotic events in each arm, as well as
the confidence interval, will be evaluated
after 24months of treatment. The
percentages of these events will be
compared by appropriate statistical test
(Chi2 test or Fisher exact method)
Secondary outcome
measures
- The type and number of side effects and
their severity (minor/major) in the HCQ
group.
- The occurrence time of side effects
- Predictive biological standard basic
parameters of the occurrence of thrombotic
events at the inclusion, M12 and M24.
- Dosage of blood level of
hydroxychloroquine at the end of the trial
will allow the measure of compliance to
HCQ
Study methodology/
scheme
○ Drug trial (phase III)
○ International multi-centre trial
○ Comparative trial
○ Randomized
○ Controlled (control group)
○ With 2 compared groups (HCQ versus
placebo)
○ Superiority
○ Double-blind (patient and investigators)
Patients will be distributed into groups
according to a 1:1 ratio.
Patients monitored in the context of their
disease (primary thrombotic APS), or with
primary thrombotic APS newly diagnosed, will
be invited to take part in the trial (incident
and prevalent cases). During each patient
report, the inclusion and non-inclusion criteria
will be checked.
After informing the patient and obtaining his/
her signature on the informed consent form,
the investigator will fill in a computerised
inclusion form, available 24/7 over the
Internet via the e-CRF (secure access
previously granted to each pre-declared
investigating centre). Randomisation will be
centralised and implemented by a
computerised random allocation system
coupled with the electronic case report form,
such that patients included in the study can be
easily and automatically randomized.
Study treatment will be prescribed and the
inclusion confirmation to the coordinating
centre will be faxed.
The investigator shall perform several data
checks and collections during the inclusion
visit:
- Verification of patient eligibility criteria
- Verification of the absence of ECG
conduction disorders
- Verification of use/initiation of effective
contraception (as the VKA are teratogenic).
- Obtaining the patient's informed consent
- Obtaining the patient's clinical-biological
information (standardised data sheet)
- Prescription of an initial ophthalmic
examination (within one month of
inclusion)
- Fax to the central pharmacy for
randomisation (numbered kits will be
provided in advance in participating
centres)
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- Initiation of treatment: HCQ or placebo, at
a dose of 200mg×2/day taken once daily
(200mg/day in patients with a weight
< 45 k).
Dispensation of the treatment every 6months
by the Pharmacy Department in each centre.
Empty or not entirely empty flask will be
counted, and pills will be counted at each new
dispensation.
Ophthalmic examination will be performed
within one month after inclusion (central
visual field).
Follow-up:
Blood tests at M1, M2, M3 to check out the
tolerance of HCQ (cell blood count CBC, and
liver enzymes ASAT/ALAT).
An Electrocardiogram (ECG) will be
performed at M1.
Visits at M6, M12, M18 and M24 with clinical
examination (that belongs to the standard
follow-up of patients with primary APS),
recording of new events related and unrelated
to the trial, monitoring of therapeutic
observance, tolerance and any changes in
adjacent treatment. Biological tests at these
visits will be performed in routine as standard
follow-up of care of patients with primary
APS.
These 5 consultations (4 for the follow-up and
one for inclusion) are part of the normal
follow-up for a patient suffering from APS.
This follow-up shall be charged to the patient's
health insurance.
To insure the compliance and tolerance of
treatment, and to register any eventual side
effects phone call will be scheduled every
three months between 2 visits to check the
tolerance and observance of the treatment
(M3, M9, M15, M21).
Ophthalmic examination: visual field and
acuity at M12, and electroretinography (ERG)
at M24.
Biological tests:
- Profile on inclusion visit D0 consistent in
full blood test and platelets, creatinine,
liver tests (ASAT, ALAT), C reactive protein
(CRP), hemostasis test, i.e. prothrombin
time (TP), TCA, fibrinogen;
antiphospholipid antibodies (lupus
circulating anticoagulant, anticardiolipin
antibody, anti-B2GP1 antibody). To these
tests will be added an antinuclear antibody
assay with determination of anti-DNA and
anti-ENA if positive. These blood tests are
part of the normal follow-up for a patient
suffering from primary APS. This follow-up
shall be charged to the patient's health
insurance.
- at M1, M2, M3 full blood test and platelets
and ASAT, ALAT (minor risk of
agranulocytosis and serious hepatitis).
There are additional blood tests not
included in routine.
- At M6, M12, M18 and M24 visit tests will
be identical to those performed on
inclusion.
- Hydroxychloroquine blood dosage will be
exclusively performed at M24 (to insure to
the compliance to treatment, but also to
not affect the double-blind character of the
trial).
This will be an additional biological test, not
included in routine.
As all patients will be receiving VKA,
treatment (target INR) follow-up shall be
performed on an outpatient basis, as for all
patients receiving VKA.
A minimal monthly INR will be performed,
and the recording of the INR will be done on
patient diary book delivered at the inclusion
in the study.
These results will be included in the final trial
analysis, as the INR level has a major impact
on the risk of further thrombotic accidents.
In summary additional examinations are:
- Ophthalmic examination within one month
of inclusion, then yearly (M1, M12, M24).
A central visual filed will be performed at
inclusion, a visual field and acuity at M12,
and electroretinography (ERG) at M24.
Unblinding and statistical analysis shall be
performed at the end of the trial, i.e. at
48months. No intermediate statistical
analyses are planned as the number of events
at one year could be too low in the two arms of
the study. An independent committee survey
will check that there is no abnormal rate of
events in one of the arms of the study every
100 included patients or at least once yearly,
to check the clinical and biological tolerance
of the experimental drug.
An independent committee of adjudication of
thrombotic events will deliberate on the
confirmation of thrombotic relapses.
As the trial involves interventional biomedical
research, it shall be declared to the competent
authorities in each country and shall be
subject to IRB approval.
Subject inclusion
criteria
• Age > 18 years• With primary* venous antiphospholipid
syndrome**, with past thrombosis, with an
indication of oral anticoagulants• Patients are volunteers, informed and
signed the consent form for participation in
the study after receiving the information
letter.• *Primary APS refers to APS with no
identified cause.
**According to the Sydney international
criteria, antiphospholipid syndrome is
evidenced by the presence of a thrombotic
clinical manifestation, combined with the
presence of a biological criterion: presence
of circulating anticoagulant and/or of
anticardiolipin antibodies > 40 uGPL
(> 99 percentiles) and/or anti-B2GP1
antibodies > 40 uGPL (> 99 percentiles).
The presence of antiphospholipid
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antibodies (aPL) should be confirmed to
3months for a APS be recognized.
The trial has taken the choice of using
(> 99 percentiles) to insure the
homogeneity and reliability of tests in the
different co-investigator centres
Subject non-inclusion
criteria
• Secondary APS• The following ophthalmological disease:
○ Retinal disease contraindicating
hydroxychloroquine prescription
○ Cataract
○ Monophthalmia• Demonstrated history of HCQ intolerance/
allergy or HCQ contraindication• Known glucose-6-phosphate
dehydrogenase deficiency• Chronic alcoholism• Patients with already increased QT values• Concurrent treatment with other products
potentially increasing QT or with
arrhythmogenic properties• Epilepsy• Haemolytic anaemia• Porphyria• Chronic liver disease• Renal failure (creatinine clearance
< 30ml/min)• Ongoing pregnancy or breast feeding• Progressive ongoing cancer or
hematological malignancy• Psychiatric disease not allowing the
treatment• Lack of health insurance• *Participation to concomitant study with
interventions leading to a bias to our study
(other drugs, with synergistic or
antagonizing or confounding effects).• Uncontrolled, active bleeding• Conditions in which coagulation tests
cannot be performed at appropriate
intervals• Any risk factor for hemorrhage (e.g.,
subacute bacterial endocarditis, blood
dyscrasias, menorrhagia, dissecting
aneurysm, major surgery, spinal
anesthesia, hemophilia, GI ulcerative
lesions, liver disease, impaired
hemostasis).• *In case of doubt with respect to this
criterion the coordinator of the study will
be contacted and will deliberate about the
possibility to participate to a concomitant
trial
Treatments/
strategies/
procedures
Patients shall be randomized in a double-
blind fashion to receive either Plaquenil or
the placebo. The ratio of patients
randomized into the two groups shall be of
1:1. Randomisation will be implemented by
a computerised random allocation system
coupled with the electronic case report form,
such that patients included in the study can
be easily and automatically randomized.
The randomisation number will be identical
to the treatment number displayed on the
treatment kit (box) labels.
The choice of a 400mg dose seemed
appropriate as this is below the toxic dose
(< 6.5mg/kg/d) and is routinely used in
cases of SLE and RA. This dose corresponds
to an average of 6mg/kg/day, the
recommended dose for patients with no
associated risk factors. Patients with such
risk factors will be excluded from the trial.
The doses used in the literature to
demonstrate the effect of HCQ on thrombotic
relapse are at least equal to this dose.
HCQ requires a certain time before being
effective. Considering the drug's
harmlessness and of the expected benefits
associated with its use, we deemed it ethical
to propose these doses over a 24-month
period.
The anti-thrombotic treatment shall consist
in VKA with a therapeutic goal freely chosen
by the investigator.
The patients' other primary treatments will
not be altered and will remain freely chosen
by the investigator.
The benefit-risk balance of this drug would
appear acceptable at the individual and
collective levels
Number of Patients Number of subjects required to answer the
research question: 350 in each group, i.e.
700
Justification of the
sample size
The sample size calculation is based on the
following justifications:
Based on previously published data
concerning the risk of thrombotic relapse in
APS, in our trial hypothesis we estimated
this risk of relapse under treatment at 10%
over 2 years, according to the results of
prospective and retrospective studies and of
the average relapse rates in APS.
On the other hand, with HCQ treatment, the
decrease of thrombosis events in secondary
APS varies between 50% and 100%. We
therefore consider that a reduction from
10% in the placebo-oral anticoagulant arm
to 5% in the HCQ-oral anticoagulant arm is
reasonable and justified in the context of this
disease. Ensuring an alpha risk of 0.05 and
an 80% test power, calculations (website
biostatTGV) indicate a number of subjects
required equal to 334 patients in each group.
Moreover, and in an independent way, to
obtain a confidence interval (at 95%) of
relapse with oral anticoagulants HCQ
between 0% and 6% (centered on 3% with a
3-point error margin), a sample of 302
patients is required.
The choice of 350 patients in each group can
satisfy the two previous conditions and
guarantee the operational feasibility of the
study.
To consider any drop-outs, the final number
of included patients shall be of 700 (350 per
group)
Statistics The trial biostatistician will perform a
statistical analysis of all randomized and
evaluated patients (intent to treat analysis).
Descriptive statistics: Collected variables
shall be described globally and per group.
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Qualitative variables are expressed in
population size and percentage. Quantitative
variables are expressed in terms of
mean ± standard deviation with 95%
confidence interval, along with the 5th and
95th percentiles. These are, however,
expressed in terms of median, minimum,
maximum and 5th and 95th percentiles
when normality is rejected. The
Kolmogorov- Smirnov test will be used to
check parameter normality and the Levene
test will be used to determine equality of
variances.
The Student t test will be used to compare
the distribution of quantitative variables
between the two patient groups (HCQ/
placebo). If the test application conditions
are not met, the Mann-Whitney non-
parametric test will be used. The Chi-square
or Fisher exact-test will be used to compare
the distributions of qualitative variables
between the two groups.
Goals analysis
The analysis of the main outcome measure
shall consist in comparing the proportions of
thrombotic events in the two groups. This
comparison shall be performed by means of
a Chi-square test, or a Fisher exact-test if the
Chi-square application conditions are not
met. If a difference between the two groups
is demonstrated for at least one of the
potential confounding variables, the main
outcome measure shall be analysed by
means of multivariate logistic regression to
consider the adjustment factors.
The secondary outcome measures will be
analysed using the same methods as the main
outcome measure. A survival analysis related
to the risk of thrombosis during follow-up
associated with the exposure factor shall be
performed and estimate by calculating the
hazard ratio (uni- and multivariate Cox
model).
We will perform analysis based on type of
antiphospholipid antibodies types and
values (low, moderate and high) and type of
previous thrombotic event (event prior to
inclusion) and we will analyse the
tendencies.
Comparative analysis will be driven if
statistical power is sufficient. In case an
increased number of adverse events recorded
at each 100 patients' inclusion, in one of the
arms of the study the trial will be stopped
according to the supervisor committee
advices
Research duration Considering the low prevalence of primary
APS in the general population, the total
patient inclusion period shall be of two
years, taking trial duration to 4 years. HCQ
requires a certain time before being
effective. Considering the drug's
harmlessness and of the expected benefits
associated with its use, we deemed it ethical
to propose these doses over a 24-month
period.
In light of the published data, the planned
follow-up period is of 24months, as this
appears to be the shortest duration allowing
us to draw conclusions and to achieve a
degree of trial significance (follow-up
> 2 years in most trials). For the same
reasons, no intermediate analyses are
planned.
Thus:
Inclusions: 24months
Follow-up: 24months, i.e.
A total duration of 4 years.
In case of pregnancy of women with primary APS enrolled in the
HIBISCUS T study, the participation to the HIBISCUS O trial will be
then proposed.
5. Trial feasibility
Considering the prevalence of primary APS in the general popula-
tion, regarding the number of patients to be included and the number of
participating international centres, including the national SLE and APS
tertiary centre, along with the duration of the inclusion period
(24months), the trial seems to be perfectly feasible.
The participation to the elaboration of the project of the French
lupus and other autoimmune disease patients' association (AFL+),
FI2AR rare disease French network, CRI-IMMIDIATE-FCRIN, E-CRIN,
EATRIS, Orphan Dev, for data management, national registry, bio-
banking and databases setting, the expertise of scientific international
Europhospholipid committee, the creation of web platform for APS
patients and the communication and valorization means are some of the
strengths of the study. A communication campaign will be launched
through Patients’ organizations, expert centers, and social networks to
optimize and facilitate the recruitment.
The participating centers possess the necessary skills, along with
significant experience in the field of APS, with a considerable enrolment
potential. Patients will be enrolled by co-investigator clinicians in-
volved in the trial, with the subsequent possibility of adding unplanned
centers wishing to include further patients, in the eventuality of a low
recruitment frequency. Patients monitored in the context of their dis-
ease, or with APS newly diagnosed by the participating departments,
will be invited to take part in the trial (incident and prevalent cases).
Potential additional clinical centres can be added.
6. Conclusion
Only a major randomized study such as the trial that we propose
could allow formal conclusions on the potential major benefits of HCQ
in thrombotic and obstetrical in APS, and on the benefit/risk balance of
such a therapy.
As all actual treatments recommended by international guidelines
are not satisfactory in terms of prevention of relapses, we are persuaded
that HCQ could bring a significant benefit both in terms of efficacy and
safety in APS patients.
This high-impact clinical study will allow formal conclusion on the
efficacy of HCQ in APS, and, based on all data on potential significant
benefit, will further lead to an application for market authorization of
HCQ in this indication.
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Take home messages
• Relapse rate in antiphospholipid syndrome (APS) is high despite
standard current therapies• Survival rate in this population is 90.1% at 10 years and 65% at
15 years• There is a need for additional or alternative therapies in this disease• An international multicenter trial on Hydroxychloroquine for the
secondary prevention of relapses in primary antiphospholipid syn-
drome is launched• Fifty three centers from 16 countries participate to this international
trial
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